Inaction over the next few months could cost tens of thousands of lives. Here are things you should do now to stay safe and to stop the spread of the coronavirus.
Two pharma companies have announced early COVID-19 vaccine trial results with over 90 per cent effectiveness. What does that mean for getting back to normal?
Asking these four questions can help us identify good news when we see it, be more critical of news reports, or delay our judgement until we have more information.
There are two new COVID-19 vaccines that appear to be more than 90% effective. But what are these vaccines, and how are they different from those used previously?
Moderna’s shot is far easier to store and distribute than Pfizer’s. But there are concerns neither vaccine performs particularly well for older people.
There’s no guarantee future COVID-19 vaccines will work in the elderly. So we can consider vaccinating the young first to protect them. Here’s what we need to work out first.
Liz Minchin, The Conversation and Molly Glassey, The Conversation
Watch two of Australia and New Zealand’s top vaccine and virus experts answering questions about COVID-19. This was filmed at a Conversation reader event with Avid Reader bookshop.
Ronald Labonte, L’Université d’Ottawa/University of Ottawa and Mira Johri, Université de Montréal
The TRIPS waiver makes COVID-19 treatments more accessible globally by enabling manufacture and distribution of COVID-19 drugs and medical supplies that would normally be protected by patents.
Two more COVID-19 vaccines may now be on the cards for Australia, should they pass clinical trials. But, as with earlier vaccine deals, there are no guarantees.
So-called mRNA vaccines are among the frontrunners in the global race to design a COVID vaccine. But as a new technology, most nations, including Australia, lack the capacity to produce them at scale.
People who oppose vaccines often are dismissed as ignorant or naive. Failing to hear their concerns and address them may only be fueling vaccine resistance, however.
Anda Nugroho, Badan Kebijakan Fiskal, Kementerian Keuangan RI
If Indonesia can maximise its role as the hub for the production and distribution of Chinese COVID-19 vaccines for Southeast Asia region, the country may gain profits.
Paediatrician at the Royal Childrens Hospital and Associate Professor and Clinician Scientist, University of Melbourne and MCRI, Murdoch Children's Research Institute